Fig. 1: Alterations as a foundation for MTB recommendations.

Oncoprint representation of alterations bearing relevance for MTB recommendations in ≥3.2% of patients (see Supplementary Fig. S1 for all alterations). Blue frames highlight individual alterations on which MTB recommendations were based for first-priority recommendations and orange frames for lower-priority recommendations. The percentage of first- and lower-priority recommendations is given on the right. The order of patients can be translated to PatID using Supplementary Table S3. The row “others” subsumes individual cases with BCL2 loss by IHC, androgen receptor expression, and FGF CNV. MSI microsatellite stability status, TMB tumour mutational burden in mutations per megabase, CUP carcinoma of unknown primary, Ca cancer, CCA cholangiocarcinoma, GIST gastrointestinal stromal tumour, HCC hepatocellular carcinoma, HNSCC head and neck squamous cell cancer, CRC colorectal cancer, NEC neuroendocrine carcinoma, RCC renal cell cancer.